Stonepine Capital Management LLC Has $2.51 Million Stake in TELA Bio, Inc. $TELA

Key Points

• Stonepine Capital Management LLC reduced its stake in TELA Bio, Inc. by 12.7%, now holding approximately 2,055,225 shares valued at $2.51 million, which makes up 2.4% of its investment portfolio.
• Multiple institutional investors have increased their positions in TELA Bio, with Jane Street Group raising its stake by 30.5% and Cubist Systematic Strategies increasing theirs by 95.3% in the most recent quarter.
• TELA Bio's shares were recently downgraded from "hold" to "sell," with the company facing a consensus rating of "Moderate Buy" and a price target of $4.50 despite reporting a quarterly EPS loss of ($0.22).

Stonepine Capital Management LLC decreased its position in shares of TELA Bio, Inc. (NASDAQ:TELA - Free Report) by 12.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,055,225 shares of the company's stock after selling 297,874 shares during the period. TELA Bio accounts for 2.4% of Stonepine Capital Management LLC's investment portfolio, making the stock its 15th biggest holding. Stonepine Capital Management LLC owned approximately 5.20% of TELA Bio worth $2,507,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Jane Street Group LLC lifted its position in TELA Bio by 30.5% during the 4th quarter. Jane Street Group LLC now owns 30,705 shares of the company's stock worth $93,000 after acquiring an additional 7,174 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in TELA Bio by 95.3% during the 4th quarter. Cubist Systematic Strategies LLC now owns 31,313 shares of the company's stock worth $95,000 after acquiring an additional 15,283 shares during the last quarter. Northern Trust Corp lifted its position in TELA Bio by 50.6% during the 4th quarter. Northern Trust Corp now owns 47,181 shares of the company's stock worth $142,000 after acquiring an additional 15,856 shares during the last quarter. Walleye Capital LLC acquired a new position in TELA Bio during the 4th quarter worth $91,000. Finally, Birchview Capital LP bought a new position in shares of TELA Bio during the 4th quarter worth about $378,000. Institutional investors and hedge funds own 94.35% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of TELA Bio from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

TELA Bio Stock Performance

NASDAQ:TELA opened at $1.77 on Friday. The firm's 50-day moving average is $1.84 and its 200-day moving average is $1.72. TELA Bio, Inc. has a 52-week low of $0.8645 and a 52-week high of $3.26. The company has a debt-to-equity ratio of 4.14, a quick ratio of 2.59 and a current ratio of 3.19. The company has a market cap of $70.13 million, a price-to-earnings ratio of -1.58 and a beta of 0.93.

TELA Bio (NASDAQ:TELA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). TELA Bio had a negative return on equity of 329.48% and a negative net margin of 54.12%.The company had revenue of $20.20 million for the quarter, compared to the consensus estimate of $20.67 million. TELA Bio has set its FY 2025 guidance at EPS. Equities research analysts anticipate that TELA Bio, Inc. will post -1.37 earnings per share for the current year.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.